Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter


Tonix Pharmaceuticals @ Marcum MicroCap Conference (TNXP) - video

Tonix Pharmaceuticals (OTC BB: TNXP) presentation at the 2012 Marcum Microcap Conference was webcast, and the video of the presentation is below.

Video streaming by Ustream

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX’s lead products are designed to be fundamental advances in sleep hygiene and pain management and to be safer and more effective than currently available treatments. TONIX’s products are the result of a program to harvest advances in science and medicine to search for potential therapeutic solutions among known pharmaceutical agents. TONIX is developing new formulations that have been optimized for new therapeutic uses. Its most advanced product candidates, TNX-102 for fibromyalgia and TNX-105 for post-traumatic stress disorder, are novel dosage formulations of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company and its pipeline of treatments for central nervous system conditions,

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Intellipharmaceutics International (NASDAQ: IPCI) @ Seeking Alpha's "Bio Pharma Momentum Movers List" | Main | Medgenics' Orphan Drug Approval For Hepatitis Therapy @ Seeking Alpha - $MDGN »